News

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Al Jazeera on MSN1d

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk's Wegovy weight loss drug sales soar 67% in second quarter

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk's weight loss challenge in five charts

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.